Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc.

MDGLยทNASDAQ

$488.15

+7.8%
HealthcareBiotechnology

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-รŸ agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

At a Glance

Live Snapshot
Market Cap$11.25B
EPS-12.8500
P/E Ratio-37.99
Earnings Date08/04/2026

No Dividend Yield Data

MDGL has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

MDGL has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

MDGL has not reported any net dividends paid values in the available annual periods.

Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. Dividend History

MDGL ยท NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

MDGL Dividend Payment History

MDGL ยท NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
mdgl

Madrigal Pharmaceuticals, Inc. Payout Ratio Analysis

MDGL ยท NASDAQ
Dividends Paid
0.00
2025
Net Income
-288.28M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.